AI assistant
TherapeuticsMD, Inc. — Director's Dealing 2018
Dec 11, 2018
35134_dirs_2018-12-10_0704be04-2879-4d40-9bb9-a6fd0ea21437.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2018-12-06
Reporting Person: Cartwright Daniel A (CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-12-06 | Common Stock | M | 40000 | $0.38 | Acquired | 40000 | Direct |
| 2018-12-06 | Common Stock | S | 40000 | $4.57 | Disposed | 40000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-12-06 | Non-Qualified Stock Option (right to buy) | $0.38 | M | 40000 | Disposed | 2021-10-21 | Common Stock (40000) | Direct |
Footnotes
F1: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.44 to $4.68, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.